AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1116357 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 3
Study 1116357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 3
Study 30640206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.5 g per day)
Number of subjects: 141
Study 30640206 — intervention group
Group type: COMPARATOR
Intervention: Olive oil supplementation
Number of subjects: 141
Study 28260993 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mask
Number of subjects: 134
Study 28260993 — intervention group
Group type: COMPARATOR
Intervention: Nasal catheter
Number of subjects: 134
Study 25277673 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical formats (line, pie, bar, or pictograph) with varying numerical information (no numbers, 1 number, or 2 numbers)
Number of subjects: 420
Study 25277673 — intervention group
Group type: EXPERIMENTAL
Intervention: Line charts
Number of subjects: 420
Study 25277673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pie charts
Number of subjects: 420
Study 25277673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictographs
Number of subjects: 420
Study 25277673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar charts
Number of subjects: 420
Study 24262416 — intervention group
Group type: EXPERIMENTAL
Intervention: Balters bionator (Group 1: 6 children, 7-8 years; Group 2: 10 children, 9-10 years)
Number of subjects: 23
Study 24262416 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 children, 8-9 years)
Number of subjects: 23
Study 22112008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-recovery intervention (treatment as usual plus recovery-promoting relationships and working practices)
Number of subjects: 435
Study 22112008 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 435
Study 22112008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-recovery intervention
Number of subjects: 435
Study 22112008 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 435
Study 18940896 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 370
Study 18940896 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 370
Study 16968570 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐12/23 monoclonal antibody (0.3, 0.75, 1.5, and 3.0 mg/kg)
Number of subjects: 20
Study 16968570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15214873 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once-daily for 5 days
Number of subjects: 430
Study 15214873 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 500 mg three-times-daily for 10 days (Control)
Number of subjects: 430
Study 15214873 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg twice-daily for 10 days (Control)
Number of subjects: 430
Study 11291826 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic SCI subjects
Number of subjects: 3
Study 11291826 — intervention group
Group type: EXPERIMENTAL
Intervention: Low thoracic SCI subjects
Number of subjects: 3
Study 11291826 — intervention group
Group type: COMPARATOR
Intervention: Non-SCI subjects
Number of subjects: 3
Study 9296504 — intervention group
Group type: EXPERIMENTAL
Intervention: New bile diversion procedure with highly selective vagotomy, antireflux procedure, and duodenal switch procedure
Number of subjects: 65
Study 8347731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubenimex (30 mg orally once a day during maintenance therapy)
Number of subjects: 195
Study 8347731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 195
Study 2872805 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 40 mg daily)
Number of subjects: 0
Study 2872805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29294356 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing for 5 minutes (DB5)
Number of subjects: 50
Study 29294356 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing for 9 minutes (DB9)
Number of subjects: 50
Study 29294356 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing for 7 minutes (DB7)
Number of subjects: 50
Study 29294356 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 50
Study 27519185 — intervention group
Group type: COMPARATOR
Intervention: Standard model of service provision at the entry point (N=1319)
Number of subjects: 3963
Study 27519185 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling and referral to add-on service with follow-up (N=1323)
Number of subjects: 3963
Study 27519185 — intervention group
Group type: EXPERIMENTAL
Intervention: Components of study arm two with the additional offer of an escort (N=1321)
Number of subjects: 3963
Study 27519185 — intervention group
Group type: EXPERIMENTAL
Intervention: All study arms
Number of subjects: 3963
Study 24103187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 21
Study 24103187 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 21
Study 22302530 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E administration (400 IU/day p.o.)
Number of subjects: 103
Study 22302530 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Vitamin E)
Number of subjects: 103
Study 20167238 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast (HF)
Number of subjects: 9
Study 20167238 — intervention group
Group type: COMPARATOR
Intervention: Low-fat isoenergetic breakfast (LFE)
Number of subjects: 9
Study 20167238 — intervention group
Group type: COMPARATOR
Intervention: Low-fat equal mass breakfast (LFM)
Number of subjects: 9
Study 18390977 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning manoeuvre and vestibular stimulated exercise training three times a week for four weeks
Number of subjects: 26
Study 18390977 — intervention group
Group type: COMPARATOR
Intervention: Canalith repositioning manoeuvre
Number of subjects: 26
Study 15941781 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction for 3 months designed to reduce body weight by 5-10%
Number of subjects: 16
Study 11772419 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 11772419 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9459535 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 8
Study 9459535 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 9459535 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study 9459535 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 8
Study 7787467 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal therapy for acute myocardial infarction
Number of subjects: 0
Study 2671517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonloading exercise program for back extensor muscles
Number of subjects: 65
Study 2671517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65
Study 2671517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (exercise and control)
Number of subjects: 65
Study 820214 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse mesh gauze, changed three times daily
Number of subjects: 20
Study 820214 — intervention group
Group type: COMPARATOR
Intervention: Formalinized xenograft
Number of subjects: 20
Study 820214 — intervention group
Group type: COMPARATOR
Intervention: Cadaver allograft
Number of subjects: 20
Study 820214 — intervention group
Group type: COMPARATOR
Intervention: Porcine xenograft
Number of subjects: 20
Study 820214 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse mesh gauze
Number of subjects: 20
Study 820214 — intervention group
Group type: COMPARATOR
Intervention: Biologic dressings
Number of subjects: 20
Study 30458234 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation (19 fractions of 3.4 Gy)
Number of subjects: 820
Study 30458234 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (39 fractions of 2.0 Gy)
Number of subjects: 820
Study 29025483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention package
Number of subjects: 371
Study 29025483 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 371
Study 26165773 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicin
Number of subjects: 48
Study 26165773 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 48
Study 23377862 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1,200 mg
Number of subjects: 50
Study 23377862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22048090 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cooling and compression
Number of subjects: 40
Study 22048090 — intervention group
Group type: COMPARATOR
Intervention: Control (no cooling and compression)
Number of subjects: 40
Study 19197823 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbioflor-2 (Escherichia coli product)
Number of subjects: 298
Study 19197823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 16478902 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 132
Study 16478902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine plus Morphine
Number of subjects: 132
Study 16478902 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine
Number of subjects: 132
Study 12734762 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline 60 mg daily for 6 months
Number of subjects: 12
Study 12734762 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 12
Study 17310047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (continuous insulin infusion to maintain intraoperative glucose levels between 4.4 and 5.6 mmol/L)
Number of subjects: 400
Study 17310047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 400
Study 17310047 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (no insulin unless glucose > 11.1 mmol/L)
Number of subjects: 400
Study 17310047 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 400
Study 10755315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (70 mg/m2 on day 1), ifosfamide (1.5 g/m2 on days 1-4), irinotecan (60 mg/m2 on days 1, 8, and 15), with rhG-CSF (1 microg/kg on days 5-18)
Number of subjects: 46
Study 10755315 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2)
Number of subjects: 46
Study 8891856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg 3 times daily)
Number of subjects: 59
Study 8891856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 2049963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral absorbable antibiotics (ofloxacin 400 mg/day and amoxicillin 20 g/day)
Number of subjects: 44
Study 2049963 — intervention group
Group type: COMPARATOR
Intervention: Oral nonabsorbable antibiotics (vancomycin 450 mg/day, tobramycin 450 mg/day, and colistin 4.5 x 10^6 units daily)
Number of subjects: 44
Study 6658041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 28373199 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin 750 mg intravenous every 12 hours (q12h)
Number of subjects: 122
Study 28373199 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg intravenous every 8 hours (q8h)
Number of subjects: 122
Study 28373199 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg intravenous every 12 hours (q12h)
Number of subjects: 122
Study 28373199 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 122
Study 27048534 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected CRC
Number of subjects: 133
Study 27048534 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic CRC
Number of subjects: 133
Study 25561129 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized water exercise training program (12 weeks, 5 times a week, 30 minutes, heart rate reserve 40-50% for weeks 1-6, 50-60% for weeks 7-12)
Number of subjects: 26
Study 25561129 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 22584091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum and counseling for smoking cessation
Number of subjects: 755
Study 22584091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755
Study 21059621 — intervention group
Group type: EXPERIMENTAL
Intervention: Bojungikki-tang (TJ-41)
Number of subjects: 40
Study 21059621 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 40
Study 17931461 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 24
Study 17931461 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 24
Study 17931461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Vildagliptin 100 mg and Simvastatin 80 mg
Number of subjects: 24
Study 15826726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic ALD patients
Number of subjects: 40
Study 15826726 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cirrhotic ALD patients
Number of subjects: 40
Study 12474486 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg single dose)
Number of subjects: 574
Study 12474486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study 9497178 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.2 g psyllium seed husk (PSH)/d
Number of subjects: 286
Study 9497178 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g PSH/d)
Number of subjects: 286
Study 9497178 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.4 g psyllium seed husk (PSH)/d
Number of subjects: 286
Study 9497178 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.8 g psyllium seed husk (PSH)/d
Number of subjects: 286
Study 7710954 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) 20 mg orally daily starting 7 days before tamoxifen (TMX)
Number of subjects: 14
Study 7710954 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TMX) 20 mg orally daily
Number of subjects: 14
Study 7710954 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT)
Number of subjects: 14
Study 2569105 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol plus amiodarone
Number of subjects: 6
Study 2569105 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol plus amiodarone
Number of subjects: 6
Study 2569105 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 6
Study 31622472 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with sleep after a 12-hour interval
Number of subjects: 0
Study 31622472 — intervention group
Group type: COMPARATOR
Intervention: Training with wakefulness after a 12-hour interval
Number of subjects: 0
Study 31622472 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a nap and polysomnography monitoring
Number of subjects: 0
Study 31622472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigma activity during NREM sleep
Number of subjects: 0
Study 30511934 — intervention group
Group type: EXPERIMENTAL
Intervention: PA projection
Number of subjects: 100
Study 30511934 — intervention group
Group type: COMPARATOR
Intervention: AP projection
Number of subjects: 100
Study 27208831 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS of left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 48
Study 27208831 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS of left primary motor cortex (M1)
Number of subjects: 48
Study 27208831 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 48
Study 24384657 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 90
Study 24384657 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 90
Study 24384657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 21687979 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and irrigation with toluidine blue O (TBO)
Number of subjects: 33
Study 21687979 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP, irrigation with TBO and low‐level laser irradiation (PDT)
Number of subjects: 33
Study 21687979 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 33
Study 19653740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pose training through a face-name association task
Number of subjects: 0
Study 19653740 — intervention group
Group type: COMPARATOR
Intervention: Illumination training
Number of subjects: 0
Study 19653740 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced level of pose training
Number of subjects: 0
Study 17879543 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingbi Tablet (Chinese herbal preparation)
Number of subjects: 120
Study 17879543 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (lesser dosage in treated group)
Number of subjects: 120
Study 17879543 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment (amethopterin, voltaren, hydroxychloroquine)
Number of subjects: 120
Study 15672845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline (7%)
Number of subjects: 24
Study 15672845 — intervention group
Group type: COMPARATOR
Intervention: Nebulised isotonic saline (0.9%)
Number of subjects: 24
Study 15672845 — intervention group
Group type: COMPARATOR
Intervention: Active cycle breathing technique (ACBT) alone
Number of subjects: 24
Study 15672845 — intervention group
Group type: COMPARATOR
Intervention: Nebulised terbutaline, nebulised IS then ACBT
Number of subjects: 24
Study 15672845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised terbutaline, nebulised HS then ACBT
Number of subjects: 24
Study 12171641 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BtxA) - 500 units injected into the biceps brachii of the paretic arm
Number of subjects: 8
Study 10524663 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen, aspirin, and caffeine (AAC)
Number of subjects: 1220
Study 10524663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1220
Study 8538485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 28
Study 8538485 — intervention group
Group type: COMPARATOR
Intervention: Placebo 500 mg/day (calcium)
Number of subjects: 28
Study 1773148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment
Number of subjects: 96
Study 1773148 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 96
Study 7041086 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodesoxycholic acid
Number of subjects: 0
Study 7041086 — intervention group
Group type: COMPARATOR
Intervention: chenodesoxycholic acid
Number of subjects: 0
Study 31887206 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary High-flow, humidified, nasal cannula (HFNC)
Number of subjects: 100
Study 31887206 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study 28693604 — intervention group
Group type: EXPERIMENTAL
Intervention: Right median nerve electrical stimulation (RMNS) at 15-20 mA, pulse width of 300 μs, 40 Hz ON for 20 s and OFF for 40 s, for 8 hours per day for 2 weeks
Number of subjects: 380
Study 28693604 — intervention group
Group type: EXPERIMENTAL
Intervention: Right median nerve electrical stimulation (RMNS)
Number of subjects: 380
Study 28693604 — intervention group
Group type: COMPARATOR
Intervention: Non-stimulation group
Number of subjects: 380
Study 26444986 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 5 mg
Number of subjects: 56
Study 26444986 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 20 mg
Number of subjects: 56
Study 26444986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 26444986 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 56
Study 24386301 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on camouflage search displays
Number of subjects: 0
Study 24386301 — intervention group
Group type: COMPARATOR
Intervention: Training on non-camouflage displays
Number of subjects: 0
Study 22287376 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL 0.25% bupivacaine with epinephrine 1:100,000 (BP)
Number of subjects: 60
Study 22287376 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 60
Study 19695030 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg administered at bedtime
Number of subjects: 40
Study 19695030 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 40 mg administered at morning
Number of subjects: 40
Study 17767673 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 116
Study 17767673 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 116
Study 17767673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 15581208 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 300 mg with alcohol
Number of subjects: 10
Study 15581208 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid (INH) 300 mg without alcohol
Number of subjects: 10
Study 11221017 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan alone
Number of subjects: 0
Study 11221017 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan in combination with cisplatin
Number of subjects: 0
Study 11221017 — intervention group
Group type: COMPARATOR
Intervention: irinotecan vs vindesine/cisplatin
Number of subjects: 0
Study 11221017 — intervention group
Group type: COMPARATOR
Intervention: irinotecan/cisplatin
Number of subjects: 0
Study 11221017 — intervention group
Group type: EXPERIMENTAL
Intervention: weekly irinotecan with weekly cisplatin
Number of subjects: 0